Group One Trading
TAK icon

Group One Trading’s Takeda Pharmaceutical TAK Stock Holding History

Group One Trading’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.2K Sell
3,900
-7,500
-66% -$132K ﹤0.01% 4992
2025
Q4 		$178K Sell
11,400
-14,900
-57% -$213K ﹤0.01% 4483
2025
Q3 		$385K Buy
26,300
+17,300
+192% +$257K ﹤0.01% 3950
2025
Q2 		$139K Buy
9,000
+1,300
+17% +$19.2K ﹤0.01% 4684
2025
Q1 		$114K Buy
7,700
+2,000
+35% +$28K ﹤0.01% 4487
2024
Q4 		$75.5K Sell
5,700
-7,900
-58% -$109K ﹤0.01% 4749
2024
Q3 		$193K Sell
13,600
-6,900
-34% -$97.9K ﹤0.01% 3648
2024
Q2 		$265K Buy
20,500
+18,700
+1,039% +$248K ﹤0.01% 3151
2024
Q1 		$25K Sell
1,800
-284,700
-99% -$4.14M ﹤0.01% 5256
2023
Q4 		$4.09M Sell
286,500
-200
-0.1% -$2.84K 0.01% 1285
2023
Q3 		$4.44M Buy
286,700
+177,400
+162% +$2.75M 0.01% 1014
2023
Q2 		$1.72M Buy
109,300
+93,600
+596% +$1.53M 0.01% 1855
2023
Q1 		$259K Sell
15,700
-47,800
-75% -$761K ﹤0.01% 3428
2022
Q4 		$991K Buy
63,500
+23,900
+60% +$334K ﹤0.01% 2412
2022
Q3 		$514K Buy
39,600
+500
+1% +$6.95K ﹤0.01% 3202
2022
Q2 		$549K Sell
39,100
-273,000
-87% -$3.9M ﹤0.01% 3330
2022
Q1 		$4.47M Sell
312,100
-389,700
-56% -$5.72M ﹤0.01% 1640
2021
Q4 		$9.57M Buy
701,800
+111,300
+19% +$1.56M 0.01% 1142
2021
Q3 		$9.67M Sell
590,500
-203,100
-26% -$3.41M 0.01% 1087
2021
Q2 		$13.4M Sell
793,600
-564,400
-42% -$9.61M 0.02% 876
2021
Q1 		$24.8M Buy
1,358,000
+1,099,000
+424% +$19.8M 0.04% 437
2020
Q4 		$4.71M Buy
259,000
+183,400
+243% +$3.22M 0.01% 1323
2020
Q3 		$1.35M Sell
75,600
-11,700
-13% -$213K ﹤0.01% 1924
2020
Q2 		$1.56M Sell
87,300
-72,800
-45% -$1.31M 0.01% 1647
2020
Q1 		$2.43M Sell
160,100
-111,100
-41% -$2.01M 0.02% 920
2019
Q4 		$5.35M Buy
271,200
+187,200
+223% +$3.58M 0.04% 642
2019
Q3 		$1.45M Buy
84,000
+25,600
+44% +$443K 0.01% 1449
2019
Q2 		$1.03M Buy
58,400
+25,100
+75% +$457K 0.01% 1568
2019
Q1 		$678K Buy
33,300
+8,700
+35% +$175K 0.01% 1705
2018
Q4 		$414K Buy
+24,600
New +$415K ﹤0.01% 2121

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading's TAK Position: Q3 2025 in Review

Group One Trading sold out of Takeda Pharmaceutical (TAK) in Q3 2025, closing a stake of 147 shares — an estimated $2.18K sold.

Group One Trading first reported a position in TAK in Q1 2019 and held it in 11 quarters. The position peaked at $754K in Q2 2022. 329 funds tracked by Wall St. Rank hold TAK as of Q3 2025.

  • Group One Trading reported no remaining Takeda Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 147 Takeda Pharmaceutical shares in Q3 2025, an estimated $2.18K.
  • Group One Trading first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 11 quarters.
  • Group One Trading's Takeda Pharmaceutical position peaked at $754K in Q2 2022.
  • 329 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.